CME/SAM. Abstract. Anatomic Pathology / Ki-67 and p53 Expression in Breast Cancer
|
|
- Valentine Davis
- 6 years ago
- Views:
Transcription
1 Anatomic Pathology / Ki-67 and p53 Expression in Breast Cancer CME/SAM Hormone Receptor Status Rather Than HER2 Status Is Significantly Associated With Increased Ki-67 and p53 Expression in Triple-Negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 Is Significantly Associated With Axillary Nodal Metastasis in Triple- Negative and High-Grade Non Triple-Negative Breast Carcinomas Jeong S. Han, MD, PhD, 1 Dengfeng Cao, MD, PhD, 2 Kyle H. Molberg, MD, 1 Venetia R. Sarode, MD, 1 Roshni Rao, MD, 3 Lisa M. Sutton, MD, 1 and Yan Peng, MD, PhD 1 Key Words: Ki-67; p53; Triple-negative; Breast cancer; Axillary nodal metastasis DOI: 1.139/AJCP9DV3EVZUATFV Upon completion of this activity you will be able to: describe the status of prognostic markers Ki-67 and p53 in triplenegative breast carcinomas vs high-grade non triple-negative breast carcinomas. discuss the difference between hormone receptor status and HER2 status in association with Ki-67 and p53 expression in triple-negative breast cancer. describe association of estrogen receptor with Ki-67 and p53 expression in high-grade breast carcinomas. define the potential prognostic value of Ki-67 in predicting axillary nodal metastasis in patients with high-grade breast cancer. The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit per article. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module. The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. Questions appear on p 311. Exam is located at Abstract Triple-negative (TN) breast carcinoma is associated with a higher recurrence rate and shorter survival and lacks the benefit of specific therapy. TN tumors usually express high levels of Ki-67 and p53 that are considered prognostic markers for breast cancer. We compared Ki-67 and p53 expression between TN and high-grade non-tn invasive carcinomas in a total of 214 cases and investigated an association between their expression and axillary nodal metastasis in these tumors. Our findings demonstrate that TN tumors are associated with significantly higher expression of Ki-67 and p53 compared with non-tn tumors, which may contribute to the poorer prognosis in TN tumors. Hormone receptor negativity rather than HER2 negativity is associated with the significantly increased Ki-67 and p53 expression in TN tumors. Furthermore, a high expression level of Ki-67 but not p53 is more likely to be associated with axillary nodal metastasis in these cases. Human breast carcinomas represent a collection of diverse tumors that vary in their natural history and responsiveness to therapy. Previous studies have classified breast carcinomas into different subtypes mainly based on their molecular and immunohistochemical profiles of hormonal receptors and human epithelial growth factor receptor 2 (HER2) overexpression. 1-4 Triple-negative (TN) breast carcinoma is characterized by negativity for estrogen receptor (ER), progesterone receptor (PR), and HER2. TN breast carcinoma is a high-risk tumor that lacks the benefit of specific therapy that targets these proteins. TN breast cancer is associated with a higher histologic grade, shorter survival, and a higher recurrence rate. 5 TN tumors usually express high levels of Ki-67 and p53 that are currently considered prognostic markers for patients with breast cancer. 1,2 Ki-67, proliferation index, is a nonhistone nuclear protein that is closely linked to proliferating cells. High Ki-67 expression has been shown to be associated with a higher histologic grade, larger tumor size, the presence of axillary lymph nodal metastasis, and shorter disease-free and overall survival in patients with breast cancer. 2,3,6-8 In addition, a positive correlation between Ki-67 expression and pathologic tumor response to neoadjuvant chemotherapy has been reported, implicating its role in response to treatment. 9 Some researchers used meta-analysis to unify various results of previous studies; they identified 524 genes that were significantly 23 Am J Clin Pathol 211;135: Downloaded 23 from DOI: 1.139/AJCP9DV3EVZUATFV
2 Anatomic Pathology / Original Article associated with breast cancer survival and found that 7% of these genes were strongly correlated with proliferation. 1 This meta-analysis highlighted the important role of proliferation in breast cancer prognosis. The p53 gene encodes for a 53-kDa nuclear phosphoprotein, which has been implicated in controlling cell-cycle regulation, differentiation, DNA repair, and apoptosis Unlike normal p53, nonfunctional mutated p53 accumulates in the nucleus of tumor cells, and, therefore, it can be detected by immunohistochemical analysis. Multiple studies have shown that p53 overexpression in breast cancer is associated with a worse outcome. 11 Recent studies suggested that p53 status might have a different predictive value for the efficacy of anthracycline/alkylating agent based chemotherapy regimen between TN and non-tn breast cancers. 14 The aims of our study were to compare Ki-67 and p53 expression between TN (histologic grade II or grade III tumors) and high-grade (grade II or grade III) non-tn invasive breast carcinomas, respectively, and to investigate an association between their expression and axillary nodal metastasis with an attempt of exploring a cutoff value of these markers in predicting nodal metastasis in these cases. We also further analyzed differential expression of Ki-67 and p53 in subgroups of non-tn tumors (ER+/PR±/HER2, ER+/PR±/ HER2+, and ER /PR /HER2+) to determine which biomarker (hormone receptors vs HER2) was correlated with Ki-67 and p53 overexpression. Materials and Methods This study was approved by the institutional review board. A total of 214 cases of high-grade carcinoma of the breast from the surgical pathology files of the University of Texas Southwestern Medical Center, Dallas, and Parkland Memorial Hospital, Dallas, between 23 and 29 were included in this study. Clinical information was obtained from electronic medical records. Clinical characteristics and immunohistochemical tumor profiles were analyzed in 81 TN tumors and 133 non-tn tumors. Of the 133 non-tn tumors, 18 (13.5%) were ER /PR /HER2+, 18 (13.5%) were ER+/ PR±/HER2+, and 97 (72.9%) were ER+/PR±/HER2. The expression of Ki-67 and p53 was compared between the TN and non-tn groups. In addition, we compared the Ki-67 and p53 expression between the TN tumors with nodal metastasis (32/81 [4%]) and the non-tn tumors with nodal metastasis (63/133 [47.4%]). Subsequently, the TN and non-tn tumors were combined as a whole (n = 214) and then divided into 2 subgroups based on the percentage of Ki-67+ and p53+ tumor cells (high Ki-67 or high p53 group, >1%; low Ki-67 or low p53 group, 1%), and ER expression and the percentage of positive axillary lymph nodes were compared between the 2 subgroups as well. Immunohistochemical Assay and Image Quantitation Methods We used quantitative immunohistochemical analysis to determine ER, PR, HER2, Ki-67, and p53 expression in the breast tumors. Immunohistochemical staining was performed using a TechMate 1 automated immunostainer (Ventana Medical Systems, Tucson, AZ). A known positive control section was included in each run to ensure proper staining. Rabbit immunoglobulin fraction (normal) or nonspecific IgG1 monoclonal diluted with phosphate-buffered saline was used as a negative control. Monoclonal antibodies were used for ER (1D5, prediluted, Ventana Medical Systems), PR (PgR, prediluted, Ventana Medical Systems), HER2 (dilution 1:1,2; DakoCytomation, Carpinteria, CA), Ki-67 (MIB-1, prediluted, Ventana Medical Systems), and p53 (DO-7, 1:16,; DAKO). Quantitative information for staining was obtained using the automated microscopy method, Automated Cellular Imaging System (ACIS, Clarient, San Juan Capistrano, CA). The ACIS system consisted of an automated robotic bright-field microscope module, a computer, and a Windows NT based software interface. The robotic microscope module scanned the immunohistochemically stained slides, and the computer monitor displayed the digitalized tissue images. After viewing the high-magnification images on the ACIS computer, several subregions of the digitalized tissue images were selected for analysis by the ACIS. To assess the level of tissue ER and PR expression, the ACIS provided the percentage of positively stained cells for ER and PR in the selected subregions. We used the manufacture s guidelines for the ACIS to determine tissue ER, PR, and HER2 expression. When the percentage of cells staining positive for ER and PR was 5% or more, the tumor was considered positive for ER and PR expression. Ki-67 and p53 were considered as high expression when positive cells were more than 1% and as low expression when positive cells were 1% or less. To assess HER2 overexpression, the ACIS provided an average score for 5 selected subregions of the tissue with the highest staining intensity for HER2. Greater than 3% of tumor cells stained with an average intensity score of 2. or more were considered to have HER2 overexpression (3+). A score of more than 1.4 to less than 2. was considered a borderline result (2+, 1%-3% of tumor cells stained), and a score of less than 1.4, negative ( or 1+, <1% of tumor cells stained). All of the results were confirmed by manual review by a pathologist (Y.P.). The criteria for determining triple negativity were based on immunohistochemical analysis and image quantitation of ER, PR, and HER2. Negative results were based on less than 5% positive staining of ER or PR, and staining of or 1+ for HER2. All positive, borderline, or negative HER2 results by immunohistochemical analysis were confirmed by fluorescent in situ hybridization. Positivity of Ki-67 and p53 was determined Downloaded from Am J Clin Pathol 211;135: DOI: 1.139/AJCP9DV3EVZUATFV 231
3 Han et al / Ki-67 and p53 Expression in Breast Cancer by the presence of nuclear staining. Grading was based on the percentage of stained tumor cells. A favorable prognostic category for both biomarkers is considered to be less than or equal to 1% of tumor cells staining positively. HER2 Fluorescent In Situ Hybridization Two of the unstained slides were cut at a 4-μm thickness. Dual-color fluorescent in situ hybridization was performed with the HER2 probe labeled with spectrum red and chromosome 17 specific centromere (D17Z1) probe labeled with spectrum green on sections cut from the same block. Deparaffinization, in situ hybridization, and staining were performed using the PathVysion kit (Abbott-Vysis Laboratories, Abbott Park, IL) per the manufacturer s protocols. Fluorescent signals in at least 6 nonoverlapping interphase nuclei with intact morphology were scored with a 1 objective, using a triple band-pass filter that permits simultaneous blue, green, and red colors. Only tumor cells from the site designated on the H&E-stained slide by the pathologist were scored for the number of red (HER2) and green (chromosome 17) signals. A case was scored as amplified if the ratio of the number of fluorescent signals of HER2 to chromosome 17 was greater than 2.2. Statistical Analysis Tumor size, mean age, and the expression of Ki-67 and p53 were compared between the TN and non-tn groups by 1-way analysis of variance with the Tukey post hoc test. Ki-67 and p53 expression was individually compared with ER and HER2 expression using the Pearson correlation test. Numbers of lymph nodes with metastasis were compared between high Ki-67 and low Ki-67 groups and between the high p53 and low p53 groups using the Fisher exact test. Results Comparison of Ki-67 and p53 Expression Between TN Tumors and Non-TN Tumors Ki-67 expression in the TN group (mean ± SE, 63.7% ± 3.6%) was significantly higher than that in the non-tn group (3.3% ± 2.4%; P <.1; unpaired t test). Similarly, p53 expression in the TN group (5.7% ± 4.8%) was significantly higher than that in the non-tn group (19.3% ± 2.9%; P =.45; unpaired t test). In addition, the TN tumors were significantly larger than the non-tn tumors (3.18 ±.45 cm vs 2.31 ±.21 cm; P <.5; unpaired t test). Subsequently, the non-tn tumors were further classified into 3 subgroups based on their hormone receptor (ER and/or PR) and HER2 status as follows: ER+/PR±/HER2, ER /PR /HER2+, and ER+/PR±/HER2+. Mean age of the patients, tumor size, and Ki-67 and p53 expression in the TN tumor group and the 3 subgroups of non-tn tumors are summarized in Table 1. The TN (ER /PR /HER2 ) and the ER /PR /HER2+ groups seemed to have younger patient populations; however, the mean age difference among the groups did not reach statistical significance (P =.1). A significant difference was observed in tumor size among the groups (P =.35), and the ER+/PR±/HER2 group showed a smaller average tumor size compared with the other groups. Differential expression of Ki-67 and p53 in subgroups is shown as mean percentage ± SEM in Table 1 and in graphs in Figure 1. Statistical significance values between groups (1-way analysis of variance followed by the Tukey post hoc test) are indicated in Figures 1A and 1B. Figure 1A shows that Ki-67 expression in the TN tumors was significantly increased compared with that in the non-tn tumors that were ER+/ PR±/HER2 (P <.1) or ER+/PR±/HER2+ (P <.1). However, there was no significant difference in Ki-67 expression between the TN tumors (ER /PR /HER2 ) and the non- TN tumors that were ER /PR /HER2+. Figure 1B illustrates that p53 expression in the TN tumors was significantly higher compared with the non-tn tumors that were ER+/PR±/ HER2 (P <.1) or ER+/PR±/HER2+ (P <.1), while there was no significant difference in p53 expression between the TN tumors and the non-tn tumors that were ER /PR / HER2+. Moreover, there was no significant difference in Ki-67 and p53 expression between ER+/PR±/HER2 and ER+/PR±/HER2+ subgroups of the non-tn tumors. In addition, Ki-67 expression in the ER /PR /HER2+ subgroup was higher than that in the ER+/PR±/HER2+ subgroup (56.2 ± Table 1 Mean Age, Tumor Size, Ki-67 Activity, and p53 Expression in TN Tumors and Non-TN Tumors in Three Subgroups * Non-TN Tumors TN Tumors ER+/PR±/HER2 (n = 97) ER+/PR±/HER2+ (n = 18) ER /PR /HER2+ (n = 18) ER /PR /HER2 (n = 81) P Age (y) 58.3 ± ± ± ± Tumor size (cm) 1.99 ± ± ± ± Ki-67 (%) ± ± ± ± 3.5 <.1 p53 (%) 9.6 ± ± ± ± 4.83 <.1 ER, estrogen receptor; PR, progesterone receptor; TN, triple negative (for ER, PR, and HER2). * Data are shown as mean ± SEM; P values obtained by 1-way analysis of variance. 232 Am J Clin Pathol 211;135: Downloaded 232 from DOI: 1.139/AJCP9DV3EVZUATFV
4 Anatomic Pathology / Original Article A Ki-67 Expression (%) ER+/PR±/HER2 ER+/PR±/HER2+ ER /PR /HER2+ ER /PR /HER2 B p53 Expression (%) ER+/PR±/HER2 ER+/PR±/HER2+ * ER /PR /HER2+ ER /PR /HER2 Figure 1 Expression of Ki-67 (A) and p53 (B) in triple-negative (TN; negative for estrogen receptor [ER], progesterone receptor [PR], and HER2) tumors and 3 subgroups of non-tn tumors. Data are shown as mean ± SEM. Statistically significant differences are indicated. * P <.5. P <.1. P <.1. One-way analysis of variance followed by the Tukey post hoc test was performed to compare individual groups vs ± 5.24), although this did not reach statistical significance. Expression of p53 in the ER /PR /HER2+ subgroup was significantly higher than that in the ER+/PR±/ HER2+ group (68.2 ± 9.3 vs 25.7 ± 8.2; P <.5). Correlation of Hormone Receptor and HER2 With Ki-67 and p53 Expression The preceding results demonstrated that hormone receptor (ER and/or PR) status rather than HER2 status was significantly associated with increased Ki-67 and p53 expression in the TN tumors. The Pearson correlation test was performed to further investigate the association between hormone receptor and HER2 status and Ki-67 and p53 expression. ER expression showed a significant negative correlation with Ki-67 expression (r =.527; P <.1) and with p53 (r =.534; P <.1). HER2 overexpression showed no significant correlation with Ki-67 expression (r =.33; P =.63) or with p53 expression (r =.78; P =.25). These findings further support our hypothesis that hormone receptor status, but not HER2 status, is closely associated with Ki-67 and p53 expression in TN breast cancers. Comparison of Ki-67 and p53 Expression Between TN Tumors With Nodal Metastasis and Non-TN Tumors With Nodal Metastasis To determine if Ki-67 and p53 expression was associated with axillary nodal metastasis in these carcinomas, we compared the Ki-67 and p53 expression between 32 TN tumors with nodal metastasis and 63 non-tn tumors with nodal metastasis. We found that the Ki-67 and p53 expression in the TN tumors with nodal metastasis was significantly higher than in the non-tn tumors with nodal metastasis (64.% ± 6.% vs 31.9% ± 3.4%; P <.1; 49.% ± 8.% vs 21.% ± 4.2%; P <.1, respectively), results similar to those of the preceding overall comparison between TN tumors and non-tn tumors. Comparison of Percentage of Positive Axillary Nodes and ER Expression of Tumors Between the High and Low Ki-67/p53 Groups To determine a cutoff value of Ki-67 and p53 expression in predicting axillary nodal metastasis in these cases, we combined the TN and non-tn tumors as a whole (n = 214) and then divided them into 2 subgroups based on the percentage of Ki-67+ or p53+ tumor cells: high Ki-67 or p53 group, more than 1%; low Ki-67 or p53 group, 1% or less. The percentages of positive axillary lymph nodes when an axillary dissection was performed were compared between the 2 subgroups. In addition, comparison of ER expression between the 2 subgroups was also conducted to further investigate the relationship between ER and Ki-67/p53 expression. The 44 tumors with low Ki-67 expression level showed significantly higher ER expression compared with the 17 tumors in the high Ki-67 group (69.3% ± 5.6% vs 41.4% ± 3.6%; P =.3; unpaired t test) Figure 2A. The 127 tumors with a low p53 expression level showed significantly higher ER expression compared with the 87 tumors in the high p53 group (65.8% ± 3.7% vs 19.8% ± 4.%; P <.1; unpaired t test) Figure 2B. These results provide further evidence that ER expression is negatively correlated with high Ki-67 and p53 expression. Downloaded from Am J Clin Pathol 211;135: DOI: 1.139/AJCP9DV3EVZUATFV 233
5 Han et al / Ki-67 and p53 Expression in Breast Cancer A 8 * B ER (%) 4 ER (%) High Ki-67 Low Ki-67 High p53 Low p53 Figure 2 Estrogen receptor (ER) expression in tumors with low vs high Ki-67 expression and low vs high p53 expression in triple-negative (TN; negative for ER, progesterone receptor, and HER2) and non-tn tumors. Data are shown as mean ± SEM. A, Expression of ER is significantly higher in the low Ki-67 group (69.3% ± 5.62%; n = 44; unpaired t test; * P =.3) compared with the high Ki-67 group (41.4% ± 3.55%; n = 17). B, Expression of ER is significantly higher in the low p53 group (65.8% ± 3.71%; n = 127; unpaired t test; P <.1) compared with the high p53 group (19.8% ± 3.99%; n = 87). High and low Ki-67 and p53 were defined as follows: high Ki-67, >1%; low Ki-67, 1%; high p53, >1%; and low p53, 1%. The high Ki-67 group included 17 cases. Results of sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND) were available for review in 144 of these 17 cases. A total of 1,35 lymph nodes from the 144 cases were examined, and 386 of them were positive for macrometastasis (386/135 [29.6%]). The low Ki-67 group had 44 cases, and results of SLNB and/or ALND were available for review in 36 of them. A total of 32 lymph nodes from the 36 cases were examined, and 49 of them were positive for macrometastasis (49/32 [16.2%]). The percentage of positive lymph nodes in the high Ki-67 group (29.6%) was significantly higher than that in the low Ki-67 group (16.2%). The contingency data were analyzed by using the Fisher exact test (P <.1) Figure 3A. The high p53 expression group had 87 cases, and results of SLNB and/or ALND were available for review in 7 of them. A total of 694 lymph nodes from the 7 cases were examined, and 183 of them were positive for macrometastasis (183/694 [26.4%]). The low p53 group had 127 cases, and results of SLNB and/or ALND were available for review in 11. A total of 913 lymph nodes from the 11 cases were examined, and 252 of them were positive for macrometastasis (252/913 [27.6%]). There was no significant difference in the percentage of positive lymph nodes between the high p53 and low p53 groups (P =.61; Fisher exact test) Figure 3B. Discussion Our study demonstrated that Ki-67 and p53 expression was significantly higher in TN breast cancers compared with high-grade non-tn tumors. This finding suggests that Ki-67 and p53 expression may have a role in a worse prognosis of TN breast cancers. It is conceivable that tumors with a worse outcome may have a higher proliferation index, Ki-67, and higher probability of mutation in tumor suppressor genes, such as p53. Because we specifically excluded low-grade (grade I) invasive carcinomas in this study, the higher expression of Ki-67 and p53 in TN tumors compared with expression in the non-tn tumors was less likely owing to their high histologic grade, which is commonly seen in TN tumors, and was more likely associated with the TN status of these breast cancers. Although previous studies showed that TN tumors had higher Ki-67 and p53 expression than non-tn tumors, 15,16 the authors did not exclude low-grade breast carcinomas in their studies for the comparison. Subsequently, we investigated whether hormone receptor negativity or HER2 negativity was associated with significantly increased Ki-67 and p53 expression in TN tumors. Our results revealed that hormone receptor (ER and/or PR) negativity, but not HER2 negativity, was significantly associated with high Ki-67 and p53 expression in TN tumors. Our analysis of subgroups based on hormone receptor and HER2 status indicated that Ki-67 and p53 expression was negatively 234 Am J Clin Pathol 211;135: Downloaded 234 from DOI: 1.139/AJCP9DV3EVZUATFV
6 Anatomic Pathology / Original Article A 1, * B 8 No. of Lymph Nodes No. of Lymph Nodes High Ki-67 Low Ki-67 High p53 Low p53 High Ki-67 Low Ki-67 LN+ LN High p53 Low p53 LN+ LN Figure 3 Association of Ki-67 and p53 expression with axillary nodal metastasis in triple-negative (TN; negative for estrogen receptor, progesterone receptor, and HER2) and non-tn tumors. A, Percentage of positive lymph nodes (LNs) in the high Ki-67 group (386/1,35 [29.6%]) is significantly higher than that in the low Ki-67 group (49/32 [16.2%]). B, High p53 and low p53 groups do not demonstrate a significant difference in the percentage of positive LNs (26.4% vs 27.6%; P >.5). Black bars, number of LNs with metastasis (LN+); white bars, number of LNs without metastasis (LN ). The contingency data were analyzed by using the Fisher exact test ( * P <.1). correlated with ER expression, but not with HER2 overexpression. Previous studies done in all types of breast carcinomas, including low-grade carcinomas, revealed that Ki-67 expression had a negative correlation with ER expression that supports our findings, but they did not examine the relationship between p53 and ER expression and the relationship between Ki-67/p53 and HER2 overexpression Owing to their higher expression in TN tumors, Ki-67 and p53 may be used as predictors for response to chemotherapeutic agents. Ki-67 overexpression has been implicated in a better response to chemotherapy agents. 9 The posttreatment Ki-67 expression level is currently considered to have significant prognostic and predictive value. 6,2,21 Although no consensus has been established so far, a few specific chemotherapy agents have been shown to be particularly effective in tumors with high Ki-67 expression. 9,22 It has been shown that breast tumors with a p53 mutation were generally ER and were associated with decreased disease-free survival. 11,14 The underlying mechanism that may involve this association is unclear. A few molecules, such as ellipticine, PRIMA-1, RITA, and MIRA-1, have been used for the restoration of p53 function, and some of them demonstrated antitumor activity during in vitro or in vivo experiments. 11 Our findings support the currently proposed molecular classification of breast cancer by gene expression profile, 4,23 in which breast carcinomas are classified into ER+ (luminal A and B) and ER (HER2+ and TN) groups. Different types of tumors were shown to have different tumor biology, different prognoses, and different responses to therapy. ER status may have a more important role than HER2 status in predicting prognosis of TN and non-tn breast cancers. In the luminal subgroup that encompasses tumors that express ER and genes related to activation of the ER pathway, the luminal B subtype of breast cancer expresses lower ER positivity and higher Ki-67 level and has a worse prognosis compared with the luminal A subtype. HER2+ tumors were originally considered to be associated with a worse prognosis in hormone receptor negative tumors. However, recent studies have shown that treatment with trastuzumab appeared to eliminate the disparity in outcomes. 24 The lack of specific therapy in TN tumors highlights the importance of further biologic characterization of these tumors, which will lead to the development of effective treatment strategies. Our findings reinforce the emerging notion that breast cancer should be classified according to its gene expression profile, in order to make accurate predictions about the outcome of the disease and select the optimal treatment for patients with breast cancer. Downloaded from Am J Clin Pathol 211;135: DOI: 1.139/AJCP9DV3EVZUATFV 235
7 Han et al / Ki-67 and p53 Expression in Breast Cancer Our study also indicated that the Ki-67 and p53 expression levels in TN tumors with nodal metastasis were significantly higher than those in non-tn tumors with nodal metastasis. To determine a cutoff value of Ki-67 and p53 expression in predicting axillary nodal metastasis in these cases, we combined the TN and non-tn tumors as a whole and then divided them into 2 subgroups: high Ki-67 or p53 (>1%) and low Ki-67 or p53 ( 1%). We found that the percentage of lymph nodes with metastasis was significantly higher in tumors with a high Ki-67 expression level compared with those with low Ki-67 expression, while there was no significant difference in the frequency of lymph node metastasis between the high p53 and low p53 groups. Some previous studies revealed that a high Ki-67 expression level was associated with more frequent lymph node metastasis in patients with all types of breast cancer, but they did not investigate an association between p53 expression and nodal metastasis. 7,25,26 Our findings demonstrated that a high expression level of Ki-67 (>1%) but not p53, although both are considered prognostic markers for breast cancer, was significantly associated with axillary nodal metastasis in patients with TN and high-grade non-tn tumors, indicating that Ki-67 has a better prognostic value than p53 for these breast carcinomas. Previous studies have demonstrated that TN breast tumors are more frequently associated with lymph node metastasis compared with non- TN tumors. Our results suggest that high Ki-67 expression may contribute to the higher risk for nodal metastasis in TN tumors. The overall prognostic value of p53 appears to be weaker than Ki-67 because a variety of studies have found conflicting data. 8,27,28 The more consistent results regarding the prognostic value of Ki-67 over p53 may be due to its significant association with higher nodal metastasis. To our knowledge, this study is the first to demonstrate that ER negativity rather than HER2 negativity is significantly associated with increased Ki-67 and p53 expression in TN breast carcinomas, and a high expression level of Ki-67, but not of p53, is significantly associated with axillary lymph node metastasis in TN and high-grade non-tn breast carcinomas. Although there appears to be significant prognostic and predictive value to an immunohistochemical assessment of Ki-67 and p53, it is still not recommended for routine clinical practice. This resistance is primarily due to continued unresolved issues regarding these markers. First, the cutoff values for Ki-67 and p53 are variable in different studies, making it difficult to conduct a comparative analysis. Standardized staining methods and image analysis are also required to achieve consistent measurement in different laboratories. Another potential problem is that the p53 overexpression detected by immunohistochemical analysis may not necessarily correlate directly with p53 mutations. Mutations of p53 are heterogeneous, and some of them may not produce a stable protein that is detectable by immunohistochemical analysis. 11 Wild-type p53 may accumulate in some conditions by binding other cellular proteins, producing positive immunohistochemical results. 11 In fact, it has been shown that correlation between immunohistochemical analysis and sequencing of p53 in breast cancers is less than 75% and that the immunohistochemical method has a lower sensitivity and specificity compared with sequence-based analysis. 29 Numerous proteins have been shown to interact with p53 and modify its activity. The p53 signaling pathway is closely linked to other signal transduction pathways such as BRCA1. 3 Although the direct mechanism is not evident at this time, our results suggest potential association between the ER signaling pathway and Ki-67 and p53 regulation. TN breast carcinomas are associated with significantly higher expression of Ki-67 and p53 compared with non- TN tumors, which may contribute to the poorer prognosis in TN tumors. Hormone receptor (ER and/or PR) negativity rather than HER2 negativity is significantly associated with the increased Ki-67 and p53 expression in TN tumors. Furthermore, high expression level of Ki-67 (>1%), but not of p53, although both are considered prognostic markers for breast cancer, is significantly associated with axillary nodal metastasis in patients with TN and high-grade non-tn tumors, indicating that Ki-67 has a better prognostic value than p53 for these breast carcinomas. From the 1 Department of Pathology and 3 Division of Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas; and 2 Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO. Presented in abstract form at the 98th Annual Meeting of the United States and Canadian Academy of Pathology; Boston, MA; March 7-13, 29; and the 99th Annual Meeting of the United States and Canadian Academy of Pathology; Washington, DC; March 2-26, 21. Address correspondence to Dr Peng: Dept of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX References 1. Hanby AM. Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br J Cancer. 25;92: Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 26;11: Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2;46: Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 21;98: Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 28;14: Am J Clin Pathol 211;135: Downloaded 236 from DOI: 1.139/AJCP9DV3EVZUATFV
8 Anatomic Pathology / Original Article 6. Jones RL, Salter J, A Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 29;116: Gonzalez-Vela MC, Garijo MF, Fernandez F, et al. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol. 21;16: Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 27;19: Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 24;4: Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 28;1:R65. doi:1.1186/ bcr Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 26;13: Lane DP. Cancer: p53, guardian of the genome. Nature. 1992;358: Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;7: Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent based regimen according to breast cancer molecular classes. Ann Oncol. 28;19: Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 28;111: Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 28;8:37. doi:1.1186/ Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer. 1997;74: Moriki T, Takahashi T, Kataoka H, et al. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbb-2 and estrogen receptor status. Pathol Int. 1996;46: Spyratos F, Ferrero-Pous M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer. 22;94: Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 27;99: Sharma S, Saboorian HM, Frawley WH, et al. MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast. Appl Immunohistochem Mol Morphol. 24;12: Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 28;17: Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 29;59: Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review [published online ahead of print November 23, 29]. J Clin Oncol. 21;28: Marrelli D, Pinto E, Neri A, et al. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: a prospective study on 675 patients. Oncol Rep. 26;15: Susini T, Nori J, Olivieri S, et al. Predicting the status of axillary lymph nodes in breast cancer: a multiparameter approach including axillary ultrasound scanning. Breast. 29;18: Erdem O, Dursun A, Coskun U, et al. The prognostic value of p53 and c-erbb-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori. 25;91: Bosari S, Lee AK, Viale G, et al. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat Histopathol. 1992;421: Norberg T, Lennerstrand J, Inganas M, et al. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cdna sequencing in human breast tumors. Int J Cancer. 1998;79: Hohenstein P, Giles RH. BRCA1: a scaffold for p53 response? Trends Genet. 23;19: Downloaded from Am J Clin Pathol 211;135: DOI: 1.139/AJCP9DV3EVZUATFV 237
Immunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationCME. CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma
Anatomic Pathology / CK5 vs CK5/6 in Breast Carcinoma CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma Rohit Bhargava, MD, 1 Sushil Beriwal, MD, 2 Kim McManus,
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
DOI 10.1007/s00268-015-3133-2 ORIGINAL SCIENTIFIC REPORT Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
ONCOLOGY REPORTS 21: 413-417, 2009 413 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer HIROKO NOGI 1, TADASHI KOBAYASHI 2, MASAFUMI SUZUKI 3, ISAO TABEI
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationRESEARCH COMMUNICATION. High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer
RESEARCH COMMUNICATION High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer Xue-Qin Yang 1,2, Fu-Bing Wang 1, Chuang Chen 1, Chun-Wei Peng 1,
More informationKi-67 is a biological tumor marker that reflects tumor
Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens Soomin Ahn, MD; Junghye Lee, MD; Min-Sun Cho, MD, PhD; Sanghui Park, MD, PhD; Sun Hee Sung, MD, PhD Context.
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationNEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE
NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationPost Neoadjuvant therapy: issues in interpretation
Post Neoadjuvant therapy: issues in interpretation Disclosure: Overview D Prognostic features in assessment of post treatment specimens: Tumor size Cellularity Grade Receptors LN Neoadjuvant chemotherapy:
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationTitle: Peritumoral Vascular Invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis
Author's response to reviews Title: Peritumoral Vascular Invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis Authors: Andrea Malfettone
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationCME. False-Positive Sentinel Lymph Nodes in Breast Cancer Patients Caused by Benign Glandular Inclusions
Anatomic Pathology / Glandular Inclusions in Sentinel Nodes False-Positive Sentinel Lymph Nodes in Breast Cancer Patients Caused by Benign Glandular Inclusions Report of Three Cases and Review of the Literature
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationPoly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer
Showa Univ J Med Sci 25 2, 83 91, June 2013 Original Poly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer Genki TSUKUDA 1 2, Yuko DATE 1, Kunio ASONUMA
More informationReporting of Breast Cancer Do s and Don ts
Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs,
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationDisclosure of Relevant Financial Relationships. Breast Pathology Evening Specialty Conference Case #4. Clinical Case: Pathologic Features
Breast Pathology Evening Specialty Conference Case #4 K.P. Siziopikou, MD, PhD Professor of Pathology Director of Breast Pathology and Breast Pathology Fellowship Program Northwestern University Feinberg
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 215 June; 18(2): 149-159 Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 213
More informationRESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India
APJCP.2016.17.6.2995 RESEARCH ARTICLE Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Dinesh Chandra Doval 1,2 *, P Suresh 1, Rupal Sinha 2, Saud Azam 2, Ullas Batra
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationCLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS
CLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS S. Chahbouni¹, A. Amarti 2, N. Hammas 3, L. Chbani 3, H. El fatemi 3 1 Department
More informationCombinatorial biomarker expression in breast cancer
Combinatorial biomarker expression in breast cancer Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis To cite this version: Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis. Combinatorial biomarker expression
More informationBreast cancer diagnostic solutions Deliver diagnostic confidence
Breast cancer diagnostic solutions Deliver diagnostic confidence 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationMolecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.
Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationKi67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
ARTICLE Ki67 Index, HER2 Status, and Prognosis of Patients With Breast Cancer Maggie C. U. Cheang, Stephen K. Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies,
More informationPathology Report Patient Companion Guide
Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.3.1187 Molecular Subtype of Breast Cancer, MVD and VEGF Expression RESEARCH ARTICLE Clinicopathologic Features of Breast Carcinomas Classified by Biomarkers
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationAndrogen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations
Anatomic Pathology / ANDROGEN RECEPTOR IN BREAST CANCER Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations S. Nicholas Agoff,
More informationResponse of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response
RESEARCH ARTICLE Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response Gamal M Elnemr 1,2 *, Ahmed H El-Rashidy 3,4, Ahmed
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationAre there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?
Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong
More informationCancer Cell Research 16 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Relationship between molecular classification and clinicopathological features of young and medium-elderly breast cancer patients Lili Li
More informationFigure S4. 15 Mets Whole Exome. 5 Primary Tumors Cancer Panel and WES. Next Generation Sequencing
Figure S4 Next Generation Sequencing 15 Mets Whole Exome 5 Primary Tumors Cancer Panel and WES Get coverage of all variant loci for all three Mets Variant Filtering Sequence Alignments Index and align
More informationResponse to Paclitaxel in Node-positive Triple Negative Breast Cancer
J Korean Surg Soc 2010;79:173-179 DOI: 10.4174/jkss.2010.79.3.173 원 저 Response to Paclitaxel in Node-positive Triple Negative Breast Cancer Department of Surgery, Kosin University College of Medicine,
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More information